Chemical Structure (Des Structure)
Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-1975
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-1975). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Figure 1)
The text describes the geometric mean ratios for maximum concentration and area under the curve for drugs in patients with varying degrees of renal and hepatic impairment, as well as in different populations based on gender and age. These ratios are expressed with 90% confidence intervals. The text also explains that ESRD stands for End Stage Renal Disease.*
Figure 2 (Figure 2)
This appears to be data from a clinical trial measuring the effect of CYP3A4 inhibitors on the drug ketoconazole. The data shows the geometric mean ratio (90% confidence interval) of the maximum concentration (Cmax) of ketoconazole in the presence of the inhibitors compared to a reference (presumably without inhibitors). The table displays two time points, with the second time point resulting in a 43% increase in ketoconazole Cmax.*
Figure 3 (Figure 3)
This is a table displaying the results of a pharmacokinetic study on Desvenlafaxine, a drug that is a substrate for both CYP2D6 and CYP3A4 enzymes. The table shows the geometric mean ratios (90% CI) for Desvenlafaxine's effects on the maximum concentration (Cmax) and area under the curve (AUC) of other drugs, such as Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The table also displays the change relative to reference values for each drug.*
Figure 4 (Figure 4)
The given text describes a graph that shows the estimated proportion of patients with relapse over time after taking Desvenlafaxine Extended-Release Tablets 50 mg or Placebo. The horizontal axis shows the time to relapse measured in days from randomization, and the vertical axis shows the estimated proportion of patients with relapse in percentage. However, the graph is not fully visible as some parts are missing.*
Figure 5 (Figure 5)
Label (Lbl713351975)
This appears to be a medication packaging label. The medication is a 25mg tablet of a drug called "Pristiq", which is packaged by a company called "Bryant Ranck Prepack". The label includes information about the manufacturer ("Yichang Humanwell OSD Plant"), the expiration date, NDC number, and storage instructions. It also includes a warning to keep the medication out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
